IDH1 and acute myeloid leukemia: IDH1/2 mutations detected in AML are predominantly heterozygous point mutations that not only render the protein incapable of carrying out decarboxylation of isocitrate, but confer it the ability to produce 2-hydroxyglutarate (2-HG), an oncometabolite, by NADPH-dependent reduction of α-KG[39].